Musculoskeletal syndromes associated with malignancy (excluding hypertrophic osteoarthropathy)

被引:34
作者
Naschitz, Jochanan E. [1 ]
Rosner, Itzhak [1 ,2 ]
机构
[1] Bnai Zion Med Ctr, Dept Internal Med A, IL-31048 Haifa, Israel
[2] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel
关键词
cancer; malignancy; musculoskeletal disorder; paraneoplastic syndrome; rheumatic disorder;
D O I
10.1097/BOR.0b013e3282f1ecd4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review To examine recent data about the association between rheumatic disorders and cancer. This article focuses on paraneoplastic rheumatic disorders, which usually precede by a short period of time the diagnosis of malignancy, and on malignant transformation, which occurs late in the course of rheumatic disorders. Evidence of causality between malignancies and rheumatic disorders was reviewed based on statistical indicators (standardized incidence ratios and odds ratios) and by applying Bradford Hill's criteria of causality. Recent findings Firm epidemiological evidence was found attesting that dermatomyositis and polymyostis may present as paraneoplastic syndromes. Several other musculoskeletal disorders may be present akin to paraneoplastic syndrome, based on clinicians' impressions, but with scarce epidemiological evidence supporting a causal determinism. In contrast, robust evidence has accumulated on the role of longstanding rheumatoid arthritis, Sjogren's syndrome and systemic sclerosis as premalignant conditions. Evidence that systemic lupus erythematosus may evolve into lymphoma is equivocal. Summary The link between malignancies and rheumatic disorders may impact on clinical practice. First, paraneoplastic rheumatic syndromes can provide the clinician with hints for earlier diagnosis of occult cancer. Second, the risk of malignant transformation during the course of rheumatic disorders may motivate the search for strategies aimed at prevention.
引用
收藏
页码:100 / 105
页数:6
相关论文
共 49 条
[1]   Paraneoplastic rheumatic syndromes [J].
András, C ;
Csiki, Z ;
Ponyi, A ;
Illés, A ;
Dankó, K .
RHEUMATOLOGY INTERNATIONAL, 2006, 26 (05) :376-382
[2]  
[Anonymous], CANC AUTOIMMUNITY
[3]   Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study [J].
Askling, J. ;
Klareskog, L. ;
Blomqvist, P. ;
Fored, M. ;
Feltelius, N. .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (09) :1184-1187
[4]   Haematopoietic malignancies in rheumatoid arthritis:: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists [J].
Askling, J ;
Fored, CM ;
Baecklund, E ;
Brandt, L ;
Backlin, C ;
Ekbom, A ;
Sundström, C ;
Bertilsson, L ;
Cöster, L ;
Geborek, P ;
Jacobsson, LT ;
Lindblad, S ;
Lysholm, J ;
Rantapää-Dahlqvist, S ;
Saxne, T ;
Klareskog, L ;
Feltelius, N .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) :1414-1420
[5]   Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis [J].
Baecklund, E ;
Iliadou, A ;
Askling, J ;
Ekborn, A ;
Backlin, C ;
Granath, F ;
Catrina, AT ;
Rosenquist, R ;
Feltelius, N ;
Sundström, C ;
Klareskog, L .
ARTHRITIS AND RHEUMATISM, 2006, 54 (03) :692-701
[6]  
Baron JA, 2003, PROG EXP TUMOR RES, V37, P1
[7]   Malignancy and autoimmunity [J].
Bernatsky, S ;
Ramsey-Goldman, R ;
Clarke, A .
CURRENT OPINION IN RHEUMATOLOGY, 2006, 18 (02) :129-134
[8]   An International Cohort Study of Cancer in Systemic Lupus Erythematosus [J].
Bernatsky, S ;
Boivin, JF ;
Joseph, L ;
Rajan, R ;
Zoma, A ;
Manzi, S ;
Ginzler, E ;
Urowitz, M ;
Gladman, D ;
Fortin, PR ;
Petri, M ;
Edworthy, S ;
Barr, S ;
Gordon, C ;
Bae, SC ;
Sibley, J ;
Isenberg, D ;
Rahman, A ;
Aranow, C ;
Dooley, MA ;
Steinsson, K ;
Nived, O ;
Sturfelt, G ;
Alarcón, G ;
Senécal, JL ;
Zummer, M ;
Hanly, J ;
Ensworth, S ;
Pope, J ;
El-Gabalawy, H ;
McCarthy, T ;
Pierre, YS ;
Ramsey-Goldman, R ;
Clarke, A .
ARTHRITIS AND RHEUMATISM, 2005, 52 (05) :1481-1490
[9]   Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].
Bongartz, T ;
Sutton, AJ ;
Sweeting, MJ ;
Buchan, I ;
Matteson, EL ;
Montori, V .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285
[10]   The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37